Investigators from the Securities and Exchange Commission have subpoenaed documents from Aveo Pharmaceuticals Inc. relating to an experimental drug for kidney cancer that was rejected by the Food and Drug Administration in June, the Cambridge company said Thursday.
In a regulatory filing, Aveo said it “intends to fully cooperate with the SEC regarding this non-public, fact-finding inquiry.”
The SEC has informed the company “that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity, or security,” according to the filing.
Aveo officials do not intend to comment publicly beyond the filing, a company spokesman said Thursday night.
Robert WeismanRobert Weisman can be reached at firstname.lastname@example.org. Follow him on Twitter @GlobeRobW.